Genome Editing in Engineered T Cells for Cancer Immunotherapy-Reference-Cited by-同舟云学术

Genome Editing in Engineered T Cells for Cancer Immunotherapy

Published:2023-09-01 Issue:17-18 Volume:34 Page:853-869
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Bonini Chiara¹^ORCID,Chapuis Aude G.²³,Hudecek Michael⁴,Guedan Sonia⁵,Magnani Chiara⁶,Qasim Waseem⁷,

Affiliation:

1. Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele Scientific Institute, Milan, Italy.

2. Program in Immunology, Division of Translational Sciences and Therapeutics, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

3. Department of Oncology, University of Washington, Seattle, Washington, USA.

4. Lehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

5. Department of Hematology and Oncology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.

6. Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Comprehensive Cancer Center Zurich (CCCZ), Zurich, Switzerland.

7. UCL Great Ormond Street Institute of Child Health, London, United Kingdom.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/hum.2023.128

Reference202 articles.

1. Adoptive cell transfer as personalized immunotherapy for human cancer

2. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up

3. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors

4. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA

5. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy;Computers in Biology and Medicine;2024-11

2. Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors;Cancer Immunology Research;2024-06-12

3. Genome editing in food and agriculture: from regulations to consumer perspectives;Current Opinion in Biotechnology;2024-06

4. CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition;Nature Communications;2024-04-26

5. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies;Frontiers in Immunology;2024-04-12